Table 1 Summary of the Sensitivity and specificity of plasma nucleosomes to detect a variety of canine cancers. (AUC- Area under the curve, Hist Sarc- Histiocytic Sarcoma, MCT- Mast cell tumor)
Cancer Histology | Number of cases | Increased Nu.Q® level | Sensitivity | Specificity | AUC |
|---|---|---|---|---|---|
All Cancers | 504 | 251/504 | 49.8% | 97% | 68.74% |
Lymphoma | 126 | 97/126 | 76.98% | 97% | 87.83% |
Hemangiosarcoma | 77 | 63/77 | 81.82% | 97% | 91.74% |
Histiocytic Sarcoma | 26 | 14/26 | 53.85% | 97% | 83.01% |
Hist Sarc—bone | 5 | 1/5 | 20% | 97% | 81.04% |
Hist Sarc Visceral | 21 | 13/21 | 61.9% | 97% | 83.48% |
Melanoma (all) | 49 | 21/49 | 42.86% | 97% | 70.36% |
Melanoma [22] | 42 | 21/42 | 50% | 97% | 75.05% |
Melanoma (cutaneous) | 7 | 0/7 | 0% | 97% | 42.22% |
Mast Cell Tumor | 126 | 24/126 | 19.05% | 97% | 43.68% |
Grade 1 MCT | 9 | 3/9 | 33.33% | 97% | 44.1% |
Grade 2 MCT | 87 | 10/87 | 11.49% | 97% | 11.49% |
Grade 3 MCT | 26 | 9/26 | 34.62% | 97% | 60.7% |
Osteosarcoma | 49 | 17/49 | 34.69% | 97% | 60.17% |
Soft tissue sarcoma | 51 | 15/51 | 29.41% | 97% | 48.19% |